Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany

European Respiratory Journal

Volumn 46, Issue 6, 2015, Pages 1826-1829

  Wolfson, Lara J ^a   Gibbert, Judith ^b   Wirth, Daniel ^c   Diel, Roland ^d  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b UNIVERSITY OF COLOGNE   (Germany)

^c JANSSEN CILAG GMBH   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; PYRAZINAMIDE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

COMBINATION DRUG THERAPY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC MODEL; ECONOMICS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GERMANY; HUMAN; MARKOV CHAIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIARYLQUINOLINES; DRUG COSTS; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; GERMANY; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; NITROIMIDAZOLES; OXAZOLES; PYRAZINAMIDE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84948946648     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00811-2015     Document Type: Letter

References (26)

1. Raviglione MC. Issues facing TB control (7). Multiple drug-resistant tuberculosis. Scott Med J 2000; 45: Suppl., 52-55.
2. Raviglione MC, Smith IM. XDR tuberculosis - implications for global public health. N Engl JMed 2007; 356: 656-659.
3. World Health Oganization. Global Tuberculosis Report 2014. Geneva, World Health Oganization, 2014.
4. Schaberg T, Bauer T, Castell S, et al. Empfehlungen zur therapie, chemopravention und chemoprophylaxe der tuberkulose im erwachsenen- und kindesalter. Deutsches Zentralkomitee zur Bekampfung der tuberkulose (DZK), Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin (DGP) [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)]. Pneumologie 2012; 66: 133-171.
5. Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2012. www.rki.de/DE/Content/InfAZ/T/Tuberkulose/Download/TB2012.html Date last accessed: March 17, 2015. Date last updated: March 17, 2014.
6. Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2013. www.rki.de/DE/Content/InfAZ/T/Tuberkulose/Download/TB2013.pdf?-blob=publicationFile Date last accessed: February 12, 2015. Date last updated: December 12, 2014.
7. World Health Oganization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva, World Health Oganization, 2013.
8. Wolfson LJ, Walker A, Hettle R, et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One 2015; 10: e0120763.
9. Vassell A. Cost-Effectiveness of Introducing Bedaquiline in MDR-TB Regimens - A Exploratory Analysis. http://who.int/tb/challenges/mdr/CEA-bdqreport-final.pdf Date last accessed: February 17, 2015. Date last updated: January 26, 2015.
10. Diel R, Nienhaus A, Lampenius N, et al. Cost of multi drug resistance tuberculosis in Germany. Respir Med 2014; 108: 1677-1687.
11. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
12. Schaberg T, Otto-Knapp R, Bauer T. Kurze ubersicht uber neue medikamente zur therapie der multiresistenten tuberkulose [New drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB)]. Pneumologie 2015; 69: 282-286.
13. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. 2009. Arbeitspapier Kostenbestimmung. www.iqwig.de/download/Arbeitspapier-Kostenbestimmung-v-1-0.pdf Date last accessed: March 17, 2015. Date last updated April 22, 2015.
14. World Health Oganization. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva, World Health Oganization, 2010.
15. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
16. Janssen. Anti-Infective Drug Advisory Committee Meeting Briefing Document: TMC207 (bedaquiline) Treatment of Patients with MDR-TB. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf Date last accessed: March 17, 2015. Date last updated: November 28, 2012.
17. Institut für das Entgeltsystem im Krankenhaus. 2014. Definitionshandbuch 2015. www.g-drg.de/cms/G-DRG-System-2015/Definitionshandbuch/Definitionshandbuch-2015 Date last accessed: March 17, 2015. Date last updated: December 04, 2014.
18. Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 2012; 32: 722-732.
19. Pym A, Diacon A, Conradie F, et al. Bedaquiline as part of a multi-drug resistant tuberculosis (MDR-TB) therapy regimen: final results of a single-arm, phase II trial (C209). OP-179-02. Int J Tuberc Lung Dis 2013; 17: Suppl. 2, S236.
20. Guglielmetti L, Le D? D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
21. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-985.
22. Wolfson L, Wirth D, Jibbert J, et al. Costs and effectiveness of combination therapy with bedaquiline and other anti-tuberculosis drugs in patients with multi- and extensively drug-resistant tuberculosis in Germany. Value Health 2014; 17: A674-A675.
23. Destatis Statistisches Bundesamt. Aktuelle Sterbetafeln für das Frühere Bundesgebiet und die Neuen Länder. www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Sterbefaelle/Tabellen/SterbetafelFBNL.html Date last accessed: March 17, 2015.
24. Liu CH, Li L, Chen Z, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One 2011; 6: e19399.
25. Tiemersma EW, van der Werf MJ, Borgdorff MW, et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011; 6: e17601.
26. European Medicines Agency. Summary of opinion (initial authorisation): Deltyba. www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/002552/WC500155458.pdf Date last accessed: March 17, 2015. Date last updated: November 21, 2013.